Bayer Aktiengesellschaft ranks near the peer group median, with valuation as the main structural strength, while stability is less supportive than the other dimensions. Price action is modestly ahead of the structural profile — a mild divergence, not yet a decisive signal.
Peer-relative scores, weakest to strongest
Bayer is a global life sciences group with core businesses in pharmaceuticals, crop science, and consumer health. The company is headquartered in Germany and operates worldwide.
A steep discount at 8.7x forward P/E reflects market skepticism, but it is the persistent balance sheet and litigation risk—anchored by a negative ROIC of -1.78% and net losses of -€3.6bn—that keeps Bayer’s valuation suppressed. The core issue is not simply weak earnings, but a capital base impaired by legal and financial overhangs: despite the company’s scale and sector relevance, negative returns on invested capital and ongoing net losses indicate a business model burdened by these factors rather than cyclical weakness.
Internally, the scale of litigation provisions—€11.8bn set aside, with €5bn in payouts expected for 2026—translates directly into projected negative free cash flow, highlighting the extent of the balance sheet strain. Market confidence remains fragile, as seen in a max drawdown of -70.4% and a stability score of just 15/100, both placing Bayer at the bottom of its peer set. While Q4 2025 saw EPS and revenue beat expectations, this operational resilience is a positive signal but remains secondary to the significant legal and financial headwinds.
Recent external context reinforces this assessment. The $7.25bn glyphosate litigation settlement is a unique, company-specific overhang that continues to dominate Bayer’s risk profile, unlike most sector peers. Analyst downgrades from Zacks and DZ Bank to 'Strong Sell' increase skepticism and limit any near-term rerating potential. Bayer’s insulation from U.S. pharma tariffs offers a minor offset, but does not address the core litigation-driven risk that defines its current valuation.
Compared to Tecan and Viatris, which have their own quality challenges, Bayer’s situation is more severe and strongly company-specific. The scale and persistence of litigation-driven financial strain and negative capital returns are not mirrored by these peers, making Bayer’s discount more about company-specific overhangs than sector-wide issues.
An improved outlook would require litigation and legal settlement risk to be materially reduced and net income to return to positive on a sustained basis. Supporting improvement would include a structurally positive ROIC. Until then, Bayer appears as a company trading at a discount for understandable reasons.
Break down BAYN.DE's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.